Dr. Scherer’s commitment to oncology patients took him from medical practice to research to helming 3T Biosciences, which is developing a novel T cell targeting platform.
Jeff Coller and Michelle Kim explain the origin of the Center and how getting low-cost RNA based molecules into the hands of academics drives innovation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback